RIBBON ACQUISITION CORP COM USD0.0001 CL A 31/12/2026(SUB/RIGHT) | 10-Q: FY2025 Q2 EPS: USD 0.11

EPS: As of FY2025 Q2, the actual value is USD 0.11.

No revenue reported as the company has not commenced operations and is focused on completing its initial business combination.

Net Income: For the three months ended June 30, 2025, net income was $271,297. For the six months ended June 30, 2025, net income was $507,153.
Operating Expenses: For the three months ended June 30, 2025, operating expenses were $242,894. For the six months ended June 30, 2025, operating expenses were $428,295.
Income Earned on Marketable Securities: For the three months ended June 30, 2025, income earned on marketable securities held in the Trust Account was $514,191. For the six months ended June 30, 2025, income earned on marketable securities held in the Trust Account was $935,448.

Net Cash Used in Operating Activities: For the six months ended June 30, 2025, net cash used in operating activities was - $418,288.
Net Cash Used in Investing Activities: For the six months ended June 30, 2025, net cash used in investing activities was - $50,000,000.
Net Cash Provided by Financing Activities: For the six months ended June 30, 2025, net cash provided by financing activities was $50,710,916.
Cash at End of Period: As of June 30, 2025, cash at the end of the period was $292,628.

Accretion of Ordinary Shares Subject to Redemption Value: For the six months ended June 30, 2025, the company recorded accretion of ordinary shares subject to redemption value of $2,800,290.

Core Business Focus: The company is focused on completing its initial business combination within the prescribed timeline, which is by January 16, 2026. The company has entered into a Business Combination Agreement with DRC Medicine Inc., DRC Medicine Ltd., and DRC Merger Inc., with the goal of merging and creating a new entity, PubCo.
Non-Core Business: The company has no current operations and is solely focused on completing the business combination. There are no plans related to divestitures or emerging segments mentioned.
Priority: The primary strategy is to complete the business combination with DRC Medicine and ensure the successful transition and integration of the new entity, PubCo.